Posters

Outcome of customized corneal collagen cross-linking for keratoconus patients in Oman: 3-12 months results

Poster Details

First Author: R.Al Saidi OMAN

Co Author(s): M. Abdo   A. Bandara   J. Babu              

Abstract Details

Purpose:

To report 3-12 months outcome of customized corneal collagen crosslinking for keratoconus patients in Oman

Setting:

This prospective study is planned to carry out at the ophthalmology center, MOD-hospital, Muscat, Oman  with 12 months follow up period starting from 2nd September 2018

Methods:

Diagnosed Keratoconus patients in the age group of 12-30 with documented progression of ³ 1 diopter over 6 months period and thinnest pachymetry over 400 mm were included in the study. Epithelial ablation was done over the specific targeted area and corneal collagen  crosslinking was carried out with application of  Riboflavin followed by UVA light. The treatment area and energy levels were customized according to the topographic findings. Clinical evaluation included uncorrected distance visual acuity (UCVA), corrected distance visual acuity(BCVA), corneal topography, pachymetry and K-reading. Assessment was  scheduled as pre-op and post-op from 1, 3, 6, 9 and 12 months

Results:

Total of 54 eyes were treated from 2nd September to 17th October 2018. So far 9 months follow-up data were available in 39 eyes for analysis. 95% (37 eyes) Improved or remained stable of both UCVA & BCVA while 5 % (2 eyes) showed further deterioration. Considering the corneal steepness; 56% (22 eyes) showed a reduction in Kmax while 44% (17 eyes) showed further steepening. Change in the Topographical Keratoconus Classification(TKC); 38% (15 eyes) showed an improvement in TKC while 59% (23 eyes) remained same. Only 3% (01 eye) showed further deterioration. No adverse effects except delayed epithelial healing in one patient.

Conclusions:

Epithelium-off customized corneal collagen crosslinking (CuRV) was safe and effective in stabilizing the progression of keratoconus at 9 months for most patients in this study group. Improvements in patient visual function are noteworthy. Early results of this novel application of collagen cross-linking are encouraging and longer-term data in larger studies are required. Studies using Epi-Off CuRV with pulsed, higher dose UVA may further inform treatment parameter efficacy.

Financial Disclosure:

None